![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 4
2021
Gramatzki, Dorothee; Felsberg, Joerg; Hentschel, Bettina; Baehr, Oliver; Westphal, Manfred; Schackert, Gabriele; Tonn, Joerg Christian; Herrlinger, Ulrich; Loeffler, Markus; Pietsch, Torsten; Steinbach, Joachim Peter; Reifenberger, Guido; Roth, Patrick und Weller, Michael
(2021):
Chemotherapy for adult patients with spinal cord gliomas.
In: Neuro-Oncology Practice, Bd. 8, Nr. 4: S. 475-484
Wick, Antje; Baehr, Oliver; Schuler, Martin; Rohrberg, Kristoffer; Chawla, Sant P.; Janku, Filip; Schiff, David; Heinemann, Volker; Narita, Yoshitaka; Lenz, Heinz-Josef; Ikeda, Masafumi; Ando, Yuichi; Wick, Wolfgang; Steinbach, Joachim P.; Burger, Michael C.; Wenger, Katharina; Lassen, Ulrik; Sankhala, Kamalesh K.; Roggia, Cristiana; Genvresse, Isabelle; Munhoz, Catya; Rentzsch, Christine; Reschke, Susanne; Langer, Simon; Wagner, Markus; Kaulfuss, Stefan; Cai, Charles; Lagkadinou, Eleni; Jeffers, Michael; Pena, Carol und Tabatabai, Ghazaleh
(2021):
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
In: Clinical Cancer Research, Bd. 27, Nr. 10: S. 2723-2733
2019
Kebir, Sied; Schaub, Christina; Junold, Nina; Hattingen, Elke; Schäfer, Niklas; Steinbach, Joachim P.; Weyerbrock, Astrid; Hau, Peter; Goldbrunner, Roland; Galldiks, Norbert; Weller, Johannes; Mack, Frederic; Tzaridis, Theophilos; Baehr, Oliver; Seidel, Clemens; Schlegel, Uwe; Schmidt-Graf, Friederike; Rohde, Veit; Borchers, Christian; Tabatabai, Ghazaleh; Haenel, Mathias; Sabel, Michael; Gerlach, Rüdiger; Krex, Dietmar; Belka, Claus; Vatter, Hartmut; Proescholdt, Martin; Glas, Martin und Herrlinger, Ulrich
(2019):
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
In: Journal of Neuro-Oncology, Bd. 144, Nr. 3: S. 501-509
Herrlinger, Ulrich; Tzaridis, Theophilos; Mack, Frederic; Steinbach, Joachim Peter; Schlegel, Uwe; Sabel, Michael; Hau, Peter; Kortmann, Rolf-Dieter; Krex, Dietmar; Grauer, Oliver; Goldbrunner, Roland; Schnell, Oliver; Baehr, Oliver; Uhl, Martin; Seidel, Clemens; Tabatabai, Ghazaleh; Kowalski, Thomas; Ringel, Florian; Schmidt-Graf, Friederike; Suchorska, Bogdana; Brehmer, Stefanie; Weyerbrock, Astrid; Renovanz, Miriam; Bullinger, Lars; Galldiks, Norbert; Vajkoczy, Peter; Misch, Martin; Vatter, Hartmut; Stuplich, Moritz; Schäfer, Niklas; Kebir, Sied; Weller, Johannes; Schaub, Christina; Stummer, Walter; Tonn, Jörg-Christian; Simon, Matthias; Keil, Vera C.; Nelles, Michael; Urbach, Horst; Coenen, Martin; Wick, Wolfgang; Weller, Michael; Fimmers, Rolf; Schmid, Matthias; Hattingen, Elke; Pietsch, Torsten; Coch, Christoph und Glas, Martin
(2019):
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
In: Lancet, Bd. 393, Nr. 10172: S. 678-688